Lion Point Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Lion Point Capital’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-59,700	Closed	-$912K	–	40
2025 Q3	$912K	Sell	59,700 -39,000	-40%	-$507K	5.18%	5
2025 Q2	$873K	Hold	98,700	–	–	5.93%	8
2025 Q1	$773K	Buy	98,700 +34,700	+54%	+$291K	4.93%	9
2024 Q4	$673K	Hold	64,000	–	–	3.52%	13
2024 Q3	$839K	Sell	64,000 -18,500	-22%	-$282K	1.87%	14
2024 Q2	$1.16M	Hold	82,500	–	–	2.11%	12
2024 Q1	$1.39M	Buy	82,500 +2,500	+3%	+$37.2K	0.78%	13
2023 Q4	$1.13M	Hold	80,000	–	–	0.57%	14
2023 Q3	$824K	Buy	+80,000	New	+$1.07M	0.37%	18

Other funds holding AVDL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lion Point Capital's AVDL Position: Q4 2025 in Review

Lion Point Capital sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 59,700 shares — an estimated $912K sold.

Lion Point Capital first reported a position in AVDL in Q3 2023 and held it in 9 quarters. The position peaked at $1.39M in Q1 2024. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

Lion Point Capital reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Lion Point Capital sold 59,700 Avadel Pharmaceuticals shares in Q4 2025, an estimated $912K.
Lion Point Capital first reported a position in Avadel Pharmaceuticals in Q3 2023 and held it in 9 quarters.
Lion Point Capital's Avadel Pharmaceuticals position peaked at $1.39M in Q1 2024.
207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Lion Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.